

# EXPERIENCE OF SPIRIVA® (THIOTROPIUM BROMIDE) USE IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE PATIENTS

*T. O. Pertseva, L. I. Konopkina,  
O. V. Myronenko*

## *Summary*

The results of cholinolytic drug tiotropium (Spiriva®) application in therapy of patients with COPD II and III stages are presents in the article. The results of pulmonary function testing, evaluation of respiratory muscle strength and St.George Respiratory Questionnaire were analyzed. These data demonstrate the safety and clinical efficacy of once-daily Spiriva® (18 µg) in 8-week trial.